Clinical Trials Logo

Clinical Trial Summary

pilot clinical study, multicenter, prospective, open, nonrandomized


Clinical Trial Description

The hypothesis is that ablation targeting PVI alone for the treatment of persistent AF is less efficient that ablation targeting electrophysiologic areas with spatio-temporal-dispersion with or without PVI ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03401931
Study type Observational [Patient Registry]
Source Hospital St. Joseph, Marseille, France
Contact
Status Withdrawn
Phase
Start date January 9, 2018
Completion date January 9, 2018

See also
  Status Clinical Trial Phase
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Terminated NCT00437242 - Odiparcil QT Definitive Study Phase 1
Completed NCT00402363 - Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation Phase 3
Completed NCT00240643 - Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke Phase 2
Completed NCT00041496 - Prevention Of Recurrence Of Atrial Fibrillation Phase 2
Completed NCT04537507 - Atrial Fibrillation and Non-obstructive Coronary Lesions
Completed NCT04761315 - Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Registry)
Not yet recruiting NCT06200311 - Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men N/A
Completed NCT00911300 - Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm Phase 2